Search General Info
Search Education
Search Partnering Companies

Miguel Forte, MD, PhD

Gosselies, Belgium
CEO of Bone Therapeutics and visiting Professor at the Lisbon University in Portugal. Member of Alliance for Regenerative Medicine (ARM) Board of Directors and Executive Committee. Previously CEO of Zelluna Immunotherapy from 2017 to end of 2019. Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy (ISCT) between 2016 and 2020. From 2006 to 2010 was VP of Global Medical Affairs at UCB. In 2004, joined Nabi Pharmaceuticals as the VP of Clinical, Medical and Regulatory Affairs in Europe. After several clinical, academic and regulatory positions in the public sector in Portugal and at the EMA, spent six years with Bristol-Myers Squibb in various positions including Executive Director of Infectious Diseases, Immunology and Dermatology and VP of International Medical Organization. Holds an MD from the Faculty of Medicine of the University of Lisbon, Portugal, and a PhD in Immunology from the University of Birmingham.
Speaking In
[On Demand]
Bone Therapeutics is a listed, clinical-stage, cell therapy company committed to rebuilding lives…